SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Nawa H, Takahashi M, Patterson PH. Cytokine and growth factor involvement in schizophrenia – support for the developmental model. Mol. Psychiatry 2000; 5: 594603.
  • 2
    Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci. 2000; 23: 618625.
  • 3
    Tohmi M, Tsuda N, Watanabe Y, Kakita A, Nawa H. Perinatal inflammatory cytokine challenge results in distinct neurobehavioral alterations in rats: implication in psychiatric disorders of developmental origin. Neurosci. Res. 2004; 50: 6775.
  • 4
    Tsuda N, Tohmi M, Mizuno M, Nawa H. Strain-dependent behavioral alterations induced by peripheral interleukin-1 challenge in neonatal mice. Behav. Brain Res. 2006; 166: 1931.
  • 5
    Swerdlow NR, Geyer MA. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr. Bull. 1998; 24: 285301.
  • 6
    Suzuki E, Shintani F, Kanba S, Asai M, Nakaki T. Induction of interleukin-1β and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain. Neurosci. Lett. 1996; 215: 201204.
  • 7
    Xu H-M, Wei J, Hemmings GP. Changes of plasma concentrations of inerleukin-1α and interleukin-6 with neuroleptic treatment for schizophrenia. Br. J. Psychiatry 1994; 164: 251253.
  • 8
    McAllister CG, Van Kammen DP, Rehn TJ et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am. J. Psychiatry 1995; 152: 12911297.
  • 9
    Akiyama K. Serum levels of soluble IL-2 receptor α, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr. Res. 1999; 37: 97106.
  • 10
    Moots RJ, Al-Saffar Z, Hutchinson D et al. Old drug, new tricks: haloperidol inhibits secretion of proinflammatory cytokines. Ann. Rhuem. Dis. 1999; 58: 585587.
  • 11
    Kowalski J, Blada P, Kucia K, Madej A, Herman ZS. Neuroleptics normalize increased release of interleukin-1β and tumor necrosis factor-α from monocytes in schizophrenia. Schizophr. Res. 2001; 50: 169175.
  • 12
    Sirota P, Meiman M, Herschko R, Bessler H. Effects of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients. Pschiatry Res. 2005; 134: 151159.
  • 13
    Katila H, Appelberg B, Hurme M, Rimón R. Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr. Res. 1994; 12: 2934.
  • 14
    Barak V, Barak Y, Levine J, Nisman B, Roisman I. Changes in interleukin-1β and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J. Basic Clin. Physiol. Pharmacol. 1995; 6: 6169.
  • 15
    Sirota P, Schild K, Elizur A, Djaldetti M, Fishman P. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 1995; 19: 7583.
  • 16
    Maes M, Bosmans E, Ranjan R et al. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr. Res. 1996; 21: 3950.
  • 17
    Song C, Lin A, Kenis G, Bosmans E, Maes M. Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr. Res. 2000; 42: 157164.
  • 18
    Toyooka K, Watanabe Y, Iritani S et al. A decrease in interleukin-1 receptor antagonist expression in the prefrontal cortex of schizophrenic patients. Neurosci. Res. 2003; 46: 299307.
  • 19
    Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am. J. Psychiatry 1993; 150: 14081410.
  • 20
    Bessler H, Levental Z, Karp L, Modai I, Djaldetti M, Weizman A. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol. Psychiatry 1995; 38: 297302.
  • 21
    Baker I, Masserano J, Wyatt RJ. Serum cytokine concentrations in patients with schizophrenia. Schizophr. Res. 1996; 20: 199203.
  • 22
    Naudin J, Capo C, Giusano B, Mège JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-α in schizophrenia? Schizophr. Res. 1997; 26: 227233.
  • 23
    Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr. Res. 1997; 25: 123129.
  • 24
    Kim YK, Lee MS, Suh KY. Decreased interleukin-2 protein in Korean schizophrenic patients. Biol. Psychiatry 1998; 43: 701704.
  • 25
    Erbağci AB, Herken H, Köylüoglu O, Yilmaz N, Tarakçioglu M. Serum IL-1β, sIL-2R, IL-6, IL-8 and TNF-α in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Med. Inflamm. 2001; 10: 109115.
  • 26
    Pociot F, Mølvig J, Wogensen L, Worsaae H, Nerup J. A TaqI Polymorphism in the human interleukin-1β (IL-1β) gene correlates with IL-1β secretion in vitro. Eur. J. Clin. Invest. 1992; 22: 396402.
  • 27
    Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin. Exp. Immunol. 1995; 99: 303310.
  • 28
    Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1β genes. Eur. J. Immunol. 1998; 28: 25982602.
  • 29
    Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1β production in vitro. Scand. J. Immunol. 1998; 47: 195198.
  • 30
    Hulkkonen J, Laippala P, Hurme M. A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1β plasma levels in healthy individuals. Eur. Cytokine Netw 2000; 11: 251255.
  • 31
    Hacker UT, Erhardt S, Tschöp K, Jelinek T, Endes S. Influence of the IL-1Ra gene polymorphism on in vivo synthesis of IL-1Ra and IL-1β after live yellow fever vaccination. Clin. Exp. Immunol. 2001; 125: 465469.
  • 32
    Katila H, Hänninen K, Hurme M. Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol. Psychiatry 1999; 4: 179181.
  • 33
    Zanardini R, Bocchio-Chiavetto L, Scassellati C et al. Association between IL-1β -511C/T and IL-1RA (86bp) n repeats polymorphisms and schizophrenia. J. Psychiatr. Res. 2003; 37: 457462.
  • 34
    Kim SJ, Lee HJ, Koo HG et al. Impact of IL-1 receptor antagonist gene polymorphism on schizophrenia and bipolar disorder. Psychiatr. Genet 2004; 14: 165167.
  • 35
    Papiol S, Rosa A, Gutiérrez B et al. Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. J. Med. Genet 2004; 41: 219223.
  • 36
    Laurent C, Thibaut F, Ravassard P et al. Detection of two new polymorphic sites in the human interleukin-1β gene: lack of association with schizophrenia in a French population. Psychiatr. Genet 1997; 7: 103105.
  • 37
    Tatsumi M, Sasaki T, Sakai T et al. Genes for interleukin-2 receptor β chain, interleukin-1β, and schizophrenia: no evidence for the association or linkage. Am. J. Med. Genet. (Neuropsychiatr. Genet.) 1997; 74: 338341.
  • 38
    Chowdari KV, Xu K, Zhang F et al. Immune related genetic polymorphisms and schizophrenia among the Chinese. Hum. Immunol. 2001; 62: 714724.
  • 39
    Meisenzahl EM, Rujescu D, Kirner A et al. Association of an interleukin-1β genetic polymorphism with altered brain structure in patients with schizophrenia. Am. J. Psychiatry 2001; 158: 13161319.
  • 40
    Yang J, Si T, Ling Y et al. Association study between interleukin-1β gene (IL-1β) and schizophrenia. Life Sci. 2003; 72: 30173021.
  • 41
    Rosa A, Peralta V, Papiol S et al. Intereukin-1β (IL-1β) gene and increased risk for the depressive symptom-dimension in schizophrenia spectrum disorders. Am. J. Med. Genet. Part B 2004; 124B: 1014.
  • 42
    Saiz PA, Garcia-Portilla MP, Arango C et al. Interleukin-1 gene complex in schizophrenia: an association study. Am. J. Med. Genet. Part B 2006; 141B: 678680.
  • 43
    Hirakawa M, Tanaka T, Hashimoto Y, Kuroda M, Takagi T, Nakamura Y. JSNP: a database of common gene variations in the Japanese population. Nucleic Acids Res. 2002; 30: 158162.
  • 44
    Watanabe Y, Fukui N, Muratake T et al. Association study of a functional promoter polymorphism of the X-box binding protein 1 gene in Japanese patients with schizophrenia. Psychiatry Clin. Neurosci. 2006; 60: 633635.
  • 45
    Erdfelder E, Faul F, Buchner A. GPOWER: a general power analysis program. Behav. Res. Methods Instrum. Comput. 1996; 28: 111.